Drug Profile
LTX 401
Alternative Names: LTX-401Latest Information Update: 20 Feb 2023
Price :
$50
*
At a glance
- Originator Lytix Biopharma
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 16 Feb 2023 LTX 401 is still in preclinical development for Liver-cancer in Norway(Intratumoural)
- 16 Feb 2023 Lytix Biopharma plans to file an IND to initiate phase I of LTX 401
- 28 Jan 2023 No recent reports of development identified for preclinical development in Liver-cancer in Norway (Intratumoural)